IL149462A0 - Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor - Google Patents

Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor

Info

Publication number
IL149462A0
IL149462A0 IL14946202A IL14946202A IL149462A0 IL 149462 A0 IL149462 A0 IL 149462A0 IL 14946202 A IL14946202 A IL 14946202A IL 14946202 A IL14946202 A IL 14946202A IL 149462 A0 IL149462 A0 IL 149462A0
Authority
IL
Israel
Prior art keywords
administering
treating
mek inhibitor
neutrophil chemotaxis
inhibiting neutrophil
Prior art date
Application number
IL14946202A
Other languages
English (en)
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of IL149462A0 publication Critical patent/IL149462A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14946202A 2001-05-09 2002-05-02 Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor IL149462A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28988101P 2001-05-09 2001-05-09

Publications (1)

Publication Number Publication Date
IL149462A0 true IL149462A0 (en) 2002-11-10

Family

ID=23113527

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14946202A IL149462A0 (en) 2001-05-09 2002-05-02 Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor

Country Status (12)

Country Link
US (1) US6972298B2 (enExample)
EP (1) EP1262176A1 (enExample)
JP (1) JP2002332247A (enExample)
KR (1) KR20020085852A (enExample)
CN (1) CN1383823A (enExample)
AU (1) AU3821502A (enExample)
CA (1) CA2385412A1 (enExample)
HU (1) HUP0201542A3 (enExample)
IL (1) IL149462A0 (enExample)
NZ (1) NZ518726A (enExample)
PL (1) PL353785A1 (enExample)
ZA (1) ZA200203668B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
WO2005007616A1 (en) * 2003-07-23 2005-01-27 Warner-Lambert Company Llc Diphenylamino ketone derivatives as mek inhibitors
EP1674452A4 (en) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
WO2005040098A1 (en) 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
DE602005004286T2 (de) 2004-06-11 2009-01-02 Japan Tobacco Inc. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoä2,3-düpyrimidinderivate und verwandte verbindungen zur behandlung von krebs
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
WO2006061712A2 (en) * 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
CN103524392B (zh) 2005-10-07 2018-06-01 埃克塞利希斯股份有限公司 作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
ATE550326T1 (de) 2006-07-31 2012-04-15 Cadila Healthcare Ltd Als modulatoren von hdl einsetzbare verbindungen
US7999006B2 (en) 2006-12-14 2011-08-16 Exelixis, Inc. Methods of using MEK inhibitors
CA2686484A1 (en) * 2007-05-11 2008-11-20 Bayer Schering Pharma Aktiengesellschaft Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN101965335B (zh) 2008-01-04 2015-01-14 英特利凯恩有限责任公司 某些化学实体、组合物和方法
EP2475659B1 (en) 2009-09-08 2015-10-28 F.Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and methods of use
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
US9073927B2 (en) 2010-01-22 2015-07-07 Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii Inhibitors of PI3 kinase
PH12012501662A1 (en) 2010-02-18 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Triazolo [4,5 - b] pyridin derivatives
WO2011121317A1 (en) 2010-04-01 2011-10-06 Centro Nacional De Investigaciones Oncologicas (Cnio) Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
ES2575995T3 (es) 2010-08-05 2016-07-04 Case Western Reserve University Inhibidores de ERK para trastornos del desarrollo de la conectividad neuronal
US20120095060A1 (en) * 2010-10-14 2012-04-19 Hardie William D Methods and compositions of mitogen-activated protein kinase (mapk) pathway inhibitors for treating pulmonary fibrosis
WO2012052745A1 (en) 2010-10-21 2012-04-26 Centro Nacional De Investigaciones Oncológicas (Cnio) Combinations of pi3k inhibitors with a second anti -tumor agent
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
ME02998B (me) 2011-04-01 2018-10-20 Genentech Inc Kombinacija акт inhibiтor jedinjenja i abiraterona za upotrebu pri terapeutsкim treтiranjima
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
HRP20220319T1 (hr) 2011-05-19 2022-05-13 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Makrociklički spojevi kao inhibitori protein kinaze
WO2013005057A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) New compounds
WO2013005041A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncológicas (Cnio) Tricyclic heterocyclic compounds as kinase inhibitors
WO2013004984A1 (en) 2011-07-07 2013-01-10 Centro Nacional De Investigaciones Oncologicas (Cnio) Tricyclic compounds for use as kinase inhibitors
CA2843595C (en) 2011-08-01 2022-10-18 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SG11201502795VA (en) 2012-10-12 2015-05-28 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
US20140120060A1 (en) * 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
WO2015038743A1 (en) * 2013-09-11 2015-03-19 The Administrators Of The Tulane Educational Fund Novel anthranilic amides and the use thereof
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
SG10202007111TA (en) 2014-07-15 2020-09-29 Genentech Inc Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors
BR112018077021A2 (pt) 2016-06-24 2019-04-02 Infinity Pharmaceuticals, Inc. terapias de combinação
JP6978507B2 (ja) * 2016-11-18 2021-12-08 システィック・ファイブロシス・ファンデーション Ｃｆｔｒ増強物質としてのピロロピリミジン
WO2019073471A1 (en) * 2017-10-09 2019-04-18 Ramot At Tel-Aviv University Ltd. POTASSIUM TRPV1 AND IONIC CHANNEL MODULATORS AND USES THEREOF
WO2019204569A1 (en) * 2018-04-20 2019-10-24 Thomas Jefferson University METHOD OF USING MeK INHIBITOR TO PREVENT RADIATION INDUCED FIBROSIS
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2025043043A2 (en) * 2023-08-24 2025-02-27 Musc Foundation For Research Development Mek1 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6251943B1 (en) * 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
CA2290509A1 (en) * 1997-07-01 1999-01-14 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors
CN1163475C (zh) * 1997-07-01 2004-08-25 沃尼尔·朗伯公司 4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
GB9726851D0 (en) * 1997-12-19 1998-02-18 Zeneca Ltd Human signal transduction serine/threonine kinase
EP1043989A4 (en) * 1998-01-06 2002-09-25 Gen Hospital Corp USE OF MEK1 INHIBITORS AS PROTECTIVE AGENTS AGAINST LESIONS DUE TO ISCHEMIA
EP1140046A1 (en) 1998-12-15 2001-10-10 Warner-Lambert Company Use of a mek inhibitor for preventing transplant rejection
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
HRP20010473A2 (en) 1998-12-22 2002-08-31 Warner Lambert Co Combination chemotherapy
CA2350234A1 (en) * 1999-01-07 2000-07-13 Alexander James Bridges Treatment of asthma with mek inhibitors
CA2358438A1 (en) 1999-01-07 2000-07-13 David Thomas Dudley Antiviral method using mek inhibitors
JP2002534498A (ja) * 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤としてのベンゼンスルホンアミド誘導体およびその使用
CN1373660A (zh) 1999-07-16 2002-10-09 沃尼尔·朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
DE10017480A1 (de) 2000-04-07 2001-10-11 Transmit Technologietransfer Verwendung von Substanzen, die als MEK Inhibitor wirken, zur Herstellung eines Arneimittels gegen DNA- und RNA-Viren
ES2567260T3 (es) * 2000-04-25 2016-04-21 Icos Corporation Inhibidores de la fosfatidilinositol 3-quinasa delta humana
JP3811775B2 (ja) * 2000-07-19 2006-08-23 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー ４−ヨードフェニルアミノベンズヒドロキサム酸の酸素化エステル
AU2002249261A1 (en) 2001-03-06 2002-09-19 Axxima Pharmaceuticals Ag Use of mek inhibitors for treating inflammation and virus induced hemorrhagic shock
WO2002076496A1 (en) 2001-03-22 2002-10-03 Van Andel Institute Anthrax lethal factor inhibits tumor growth and angiogenesis

Also Published As

Publication number Publication date
CA2385412A1 (en) 2002-11-09
HU0201542D0 (enExample) 2002-07-29
KR20020085852A (ko) 2002-11-16
CN1383823A (zh) 2002-12-11
NZ518726A (en) 2004-06-25
ZA200203668B (en) 2002-12-20
AU3821502A (en) 2002-11-14
US6972298B2 (en) 2005-12-06
US20030055095A1 (en) 2003-03-20
HUP0201542A3 (en) 2003-10-28
HUP0201542A2 (hu) 2003-01-28
PL353785A1 (en) 2002-11-18
EP1262176A1 (en) 2002-12-04
JP2002332247A (ja) 2002-11-22

Similar Documents

Publication Publication Date Title
IL149462A0 (en) Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
AU5610398A (en) Method of treating or preventing septic shock by administering a mek inhibitor
HUS1600050I1 (hu) Eljárás szklerózis multiplex kezelésére
PT1983000E (pt) Método para o tratamento de esclerose múltipla através da inibição da atividade de il-17
IL164496A0 (en) Method of inhibiting restenosis
PL355305A1 (en) Method of effecting double-sided laser impact treatment of workpieces
AU2002360437A8 (en) Reducing myelin-mediated inhibition of axon regeneration
ZA200306124B (en) Method of treating of demyelinating diseases or conditions.
ZA200406910B (en) Method of treating mucus hypersecretion
GB0112216D0 (en) Method of treatment
ZA200303274B (en) Method of treating shellfish.
GB0015025D0 (en) Method of treating a steel article
GB0118892D0 (en) Method of treatment
AUPR381601A0 (en) Method of treating respiratory conditions
EP1458372A4 (en) CALCIUM L-THREONATE FOR THE PREVENTION OR TREATMENT OF CANCER DISORDERS
EP1267911A4 (en) TREATMENT METHOD
AU2003237199A1 (en) Method of treating multiple sclerosis
GB0202813D0 (en) A method of treating gas
AU2002246657A1 (en) Method of treating or preventing disease characterized by cryptococcus neoformans infection
IL147884A0 (en) A method of treating wounds by enhancing expression of procollagen
GB0123852D0 (en) Method of deriving a code
ITRN20020011A1 (it) Apparecchiatura per l'effettuazione contemporanea di un trattamento idroterapico, noto come doccia "vichy", e di un trattamento cromoterapic
AU2002240107A1 (en) Water treatment method for reducing levels of cr+6
GB0125105D0 (en) Method of treatment
GB0126094D0 (en) Method of treatment